Adlai Nortye (ANL) Stock Price, News & Analysis

Company Overview

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Key Stats

• Today's Range: $2.20 to $2.34
• 50-Day Range: $1.95 to $3.54
• 52-Week Range: $1.85 to $17.48
• Volume: 6,048 shs
• Average Volume: 11,301 shs
• Market Capitalization: $81.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Adlai Nortye Stock Analysis - MarketRank™

Adlai Nortye scored higher than 41% of companies evaluated by MarketBeat, and ranked 702nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Adlai Nortye has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adlai Nortye has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of Adlai Nortye have been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adlai Nortye has recently increased by 28.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adlai Nortye does not currently pay a dividend.

Dividend Growth

Adlai Nortye does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the outstanding shares of Adlai Nortye have been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adlai Nortye has recently increased by 28.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.25

News Sentiment

Adlai Nortye has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Adlai Nortye this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adlai Nortye insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 35.21% of the stock of Adlai Nortye is held by institutions.

ANL Stock Analysis - Frequently Asked Questions

How have ANL shares performed this year?

Adlai Nortye's stock was trading at $8.99 on January 1st, 2024. Since then, ANL shares have decreased by 75.5% and is now trading at $2.20.
View the best growth stocks for 2024 here.

When did Adlai Nortye IPO?

Adlai Nortye (ANL) raised $58 million in an initial public offering on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share.

How do I buy shares of Adlai Nortye?

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Adlai Nortye own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adlai Nortye investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), nCino (NCNO), Construction Partners (ROAD), Taiwan Semiconductor Manufacturing (TSM) and XPeng (XPEV).

Company Calendar

• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANL
• Previous Symbol: NASDAQ:ANL
• CUSIP: N/A
• CIK: 1944552
• Web: www.adlainortye.com
• Phone: 848-230-7430
• Fax: N/A
• Employees: 127
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +293.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.85
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 16.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 36,900,000
• Free Float: N/A
• Market Cap: $84.50 million
• Optionable: Not Optionable
• Beta: -0.77